Home/Hedge Fund Intelligence/Viridian Therapeutics, Inc.
Nasdaq: VRDNStockForm 13F30 Jun 2026

Hedge funds that hold Viridian Therapeutics, Inc. Nasdaq: VRDN

CUSIP 92790C104 · who reports it, how much, and how much it matters to them

32 of the 720 hedge fund managers we track reported shares of Viridian Therapeutics, Inc. (Nasdaq: VRDN) on Form 13F for 30 June 2026. Between them they reported USD 550m. The largest position belongs to Kynam Capital Management, at USD 119m.

Managers reporting it32of 720 we track
Value they reportUSD 550mshares only, 30 Jun 2026
Funds they run498with a file on PPLI.com
Largest positionUSD 119mKynam Capital Management
Typical weight0.1%median share of a manager's book
Heaviest weight6.6%Kynam Capital Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

32 managers, USD 550m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Viridian Therapeutics, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Kynam Capital Management1 fund on PPLI.comUSD 119m6.6%
2Fairmount Funds Management2 funds on PPLI.comUSD 94m6.2%
3Deep Track Capital1 fund on PPLI.comUSD 66m1.0%
4Avoro Capital Advisors1 fund on PPLI.comUSD 46m0.4%
5Baker Bros. Advisors2 funds on PPLI.comUSD 44m0.2%
6POINT72 Asset Management17 funds on PPLI.comUSD 43m0.0%
7Balyasny Asset Management25 funds on PPLI.comUSD 24m0.0%
8D. E. Shaw & Co.15 funds on PPLI.comUSD 22m0.0%
9Eversept Partners3 funds on PPLI.comUSD 15m0.8%
10Schonfeld Strategic Advisors30 funds on PPLI.comUSD 15m0.1%
11Renaissance Technologies13 funds on PPLI.comUSD 14m0.0%
12Perceptive Advisors6 funds on PPLI.comUSD 11m0.2%
13Boothbay Fund Management2 funds on PPLI.comUSD 9.9m0.1%
14Yiheng Capital Management1 fund on PPLI.comUSD 7.4m2.5%
15Capital Fund Management S.A.12 funds on PPLI.comUSD 3.6m0.0%
16Squarepoint Ops7 funds on PPLI.comUSD 3.3m0.0%
17HighVista Strategies27 funds on PPLI.comUSD 2.9m0.7%
18Lighthouse Investment Partners190 funds on PPLI.comUSD 2.2m0.1%
19Voleon Capital Management13 funds on PPLI.comUSD 1.8m0.0%
20Aquatic Capital Management3 funds on PPLI.comUSD 1.5m0.1%
21Burkehill Global Management5 funds on PPLI.comUSD 1.2m0.0%
22Tudor Investment Corporation10 funds on PPLI.comUSD 1.1m0.0%
23Greenland Capital Management1 fund on PPLI.comUSD 918,0000.1%
24Citadel Advisors32 funds on PPLI.comUSD 759,0000.0%
25Verdad Advisers6 funds on PPLI.comUSD 711,0000.7%
26Persistent Asset Partners10 funds on PPLI.comUSD 468,0000.1%
27Bayforest Capital1 fund on PPLI.comUSD 363,0000.3%
28Brevan Howard Capital Management39 funds on PPLI.comUSD 358,0000.0%
29Graham Capital Management18 funds on PPLI.comUSD 282,0000.0%
30LMR Partners2 funds on PPLI.comUSD 184,0000.0%
31The Quarry1 fund on PPLI.comUSD 4,2250.0%
32Elequin Capital2 funds on PPLI.comUSD 1,3040.0%
Next: where it matters most
Where it matters most

For Kynam Capital Management it is 6.6% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Kynam Capital ManagementUSD 119m6.6%
2Fairmount Funds ManagementUSD 94m6.2%
3Yiheng Capital ManagementUSD 7.4m2.5%
4Deep Track CapitalUSD 66m1.0%
5Eversept PartnersUSD 15m0.8%
6Verdad AdvisersUSD 711,0000.7%
7HighVista StrategiesUSD 2.9m0.7%
8Avoro Capital AdvisorsUSD 46m0.4%
9Bayforest CapitalUSD 363,0000.3%
10Baker Bros. AdvisorsUSD 44m0.2%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Viridian Therapeutics, Inc.

What is the ticker symbol of Viridian Therapeutics, Inc.?

Viridian Therapeutics, Inc. trades under the symbol VRDN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 92790C104.

Which hedge funds own Viridian Therapeutics, Inc. (Nasdaq: VRDN)?

32 of the 720 hedge fund managers PPLI.com tracks reported Viridian Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Kynam Capital Management (USD 119m), Fairmount Funds Management (USD 94m), Deep Track Capital (USD 66m), Avoro Capital Advisors (USD 46m) and Baker Bros. Advisors (USD 44m).

How many hedge funds hold Viridian Therapeutics, Inc.?

32 managers in our coverage reported it, and between them they run 498 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Viridian Therapeutics, Inc.?

Kynam Capital Management, where the position was 6.6% of the reported 13F book at 30 June 2026.

Does this show who is short Viridian Therapeutics, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Viridian Therapeutics, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.